Despite high incidence rates and severe complications, the management of xerostomia lacks clinical guidelines. The aim of this overview was to summarize the clinical experience derived from the last 10 years of treatments and prevention using systemic compounds. Results showed that the cytoprotective drug amifostine, and its antioxidant agents, are the most discussed as preventive agents of xerostomia in head and neck cancer (HNC) patients. In the presence of the disease, the pharmacological treatments have been mainly directed to stimulate secretion of the damaged salivary glands, or to counteract a decreased capacity of the antioxidant system, in view of an increasing of reactive oxygen species (ROS). However, the data demonstrated low ability of the drugs, together with a great number of side effects, which strongly limit their use. Concerning traditional medicine (TM), valid clinical trials are so limited that neither the efficacy nor the absence of interferences to concomitant chemical therapies can be validated. Consequently, the management of xerostomia and its devastating complications remain a very significant void in daily clinical practice.

Pistacia lentiscus L. (PlL) has been used for centuries in traditional medicine. The richness in antimicrobial biomolecules of Pll derivates can represent an alternative to chemically formulated agents used against oral infections. This review summarizes the knowledge on the antimicrobial activity of PlL essential oil (EO), extracts, and mastic resin against microorganisms being of relevance in oral biofilm-associated diseases. Results demonstrated that the potential of PlL polyphenol extracts has led to increasing scientific interest. In fact, the extracts are a significantly more effective agent than the other PlL derivates. The positive findings regarding the inhibition of periodontal pathogens and C. albicans, together with the antioxidant activity and the reduction of the inflammatory responses, suggest the use of the extracts in the prevention and/or reversal of intraoral dysbiosis. Toothpaste, mouthwashes, and local delivery devices could be effective in the clinical management of these oral diseases.

Background/Objectives: Taste dysfunction is a highly prevalent yet underrecognized complication among patients with head and neck cancer (HNC), significantly impairing nutritional intake, treatment adherence, and quality of life (QoL). This comprehensive review synthesizes current knowledge on the pathophysiological mechanisms and clinical management of taste dysfunction associated with HNC and its treatments, particularly chemotherapy and radiotherapy. Methods: A structured literature search was performed across PubMed, Scopus, and Cochrane Library for articles published between January 2015 and February 2025. Studies were included if they investigated taste dysfunction related to HNC, focusing on pathophysiological mechanisms and therapeutic interventions. A total of 47 original studies were analyzed through a narrative synthesis due to heterogeneity in study designs and outcomes. Results: Taste dysfunction in HNC patients arises from tumor-related inflammation, cytotoxic injury from chemotherapy, and radiation-induced epithelial and neural damage. Chemotherapy and radiotherapy often exert synergistic negative effects on gustatory function. Management strategies identified include dietary counselling, nutritional supplementation (zinc, lactoferrin, monosodium glutamate, miraculin), pharmacological agents targeting salivary function, and non-pharmacological interventions such as acupuncture, photobiomodulation, and reconstructive surgery. However, the evidence is limited by small sample sizes, methodological variability, and the frequent exclusion of HNC patients from broader dysgeusia trials. Reported prevalence of taste dysfunction ranged from 39% to 97.4%, with higher rates observed among patients treated with radiotherapy and chemoradiotherapy. Conclusions: Taste dysfunction remains a critical yet unmet clinical challenge in HNC patients. High-quality, targeted research is urgently needed to develop standardized assessments and evidence-based management strategies to improve patient outcomes.

Background: Despite incidence rates and complications, the clinical management of xerostomia lacks guidelines. Aim: The aim of this overview is to summarize the clinical experience over the past 10 years of treating xerostomia using non-pharmacological interventions. Materials and Methods: A literature search was conducted across PubMed, EMBASE, Web of Science, ScienceDirect, and Google Scholar databases, covering publications from 1 January 2013 to 30 January 2023. Results: Topical therapies are the mainstays in cases of longstanding oral dryness. Their aim is to relieve oral discomfort by retaining mouth moisture. Macro-molecular lubricants were largely used in xerostomia due to radiotherapy for Head and Neck cancer (HNC) and xerostomia due to the chronic use of drugs. However, none of them provided stable relief for dry mouth. Traditional Medicine (TM), through the administration of different medicinal herbs and plants, has recently been evaluated against xerostomia in clinical trials. Matricaria chamomilla L., Linum usitatissimum, and Malva sylvestris L. together with Althea digitata Boiss, Licorice root, and Salvia Officinalis are among the most used compounds. They were formulated as water extracts with health benefits that are attributed to the presence of polyphenols. However, the low number of clinical evaluations represents the greatest limitation for validating the efficacy of TM against xerostomia. Regarding acupuncture, it did not show significant effects in the trials in comparison to the control groups. Further, electrostimulation, photo-biomodulation and hyperbaric therapy need more randomized clinical evaluations to effectively demonstrate their ability to relieve dry mouth. Conclusions: No topical treatment has shown stable relief of xerostomia. Consequently, the management of xerostomia and its devastating complications remain a significant void in daily clinical practice.

Background and Clinical Significance: Dental demineralization is a multifactorial process influenced by biofilm activity, diet, and systemic conditions. While gastroesophageal reflux disease (GERD) is known for its role in enamel erosion, its contribution to cariogenic processes remains underexplored. Additionally, Brugada syndrome, a genetic arrhythmia disorder, may indirectly affect oral health due to medical complexities and reduced motivation for dental care. This case highlights the management of extensive mineral loss in a patient with GERD and Brugada syndrome, emphasizing the importance of personalized remineralization strategies and interdisciplinary collaboration. Case Presentation: A 27-year-old male with Brugada syndrome, treated with a subcutaneous implantable cardioverter defibrillator (S-ICD), presented with widespread enamel demineralization, multiple active carious lesions, and gingival inflammation. Clinical evaluation revealed a high DMFT index (15), significant plaque accumulation, and an oral pH of 5.8, indicating an elevated risk of mineral loss. Poor hygiene habits, frequent sugar intake, and GERD-related acid exposure contributed to his condition. The therapeutic approach included patient education, fluoride-functionalized hydroxyapatite toothpaste and mousse, dietary modifications, and restorative procedures. After 120 days, improvements included enhanced enamel integrity, a reduction in plaque index (from 50% to 25%), and the resolution of gingival inflammation (BOP: 38% to 12%). Conclusions: This case underscores the importance of an integrated approach to managing dental demineralization in patients with systemic conditions. The combination of remineralization therapy, behavioral modifications, and structured follow-up yielded significant clinical benefits. Further research is needed to develop standardized protocols for individuals at high risk due to systemic factors affecting oral health.

Background/Objectives: Dental caries remains one of the most prevalent chronic diseases in early childhood, and traditional preventive strategies often fail to achieve sustained risk reduction without individualized management. The Caries Management by Risk Assessment protocol (CAMBRA) provides a structured, risk-based preventive approach integrating clinical and behavioral indicators. This study evaluated the two-year effectiveness of a CAMBRA-based prevention program in preschool children. Methods: A prospective observational cohort study was conducted in a university-affiliated pediatric dentistry clinic in Italy. A total of 296 children aged 4–6 years were enrolled and classified into caries risk categories according to CAMBRA criteria. Personalized preventive plans included oral hygiene education, dietary counselling, fluoride applications, and sealants where indicated. Clinical outcomes were assessed over a 24-month follow-up period. Results: Over two years, a substantial shift toward lower caries risk categories was observed, with the proportion of children classified as High/ Very High risk markedly reduced. Improvements were also recorded in caries experience (dmft) and oral hygiene status (OHI-S). Greater adherence to scheduled follow-up visits was associated with a higher likelihood of clinical improvement. Conclusions: A CAMBRA-based, risk-guided preventive program implemented in a public pediatric dental setting was associated with meaningful improvements in caries risk profiles and oral health parameters over 24 months. Regular follow-up and caregiver engagement appear to be key factors in sustaining preventive benefits in high-risk preschool populations.